---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-042919"
form_type: "8-K"
ticker: null
cik: "0001733413"
company_name: "TFF Pharmaceuticals, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:05:42.650194+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TFF Pharma Q1 net loss $5.7M, cash $3.2M; raised $6M in public offerings since March

## Summary
- Net loss of $5.7M improved from $7.1M in Q1 2023; R&D spend $3.6M, G&A $2.4M.
- Cash and equivalents $3.2M at March 31; completed $4.8M offering May 1, plus $1.2M in March.
- Phase 2 TFF TAC: 8/8 patients transitioned from oral; 4/4 completed 12 weeks and entered extension.
- TFF VORI: 5/6 patients achieved clinical and mycologic response; no IPA-related mortality.
- Company prioritizing TFF TAC; exploring strategic alternatives for TFF VORI; FDA feedback expected in Q2.

## SEC filing metadata
- accession: 0001213900-24-042919
- form_type: 8-K
- cik: 0001733413
- company_name: TFF Pharmaceuticals, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733413/000121390024042919/0001213900-24-042919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733413/000121390024042919/ea0206069-8k_tffpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-042919
- JSON: https://secwatch.observer/filing/0001213900-24-042919.json
- Plain text: https://secwatch.observer/filing/0001213900-24-042919.txt

## Key facts
- Earnings Releases
  TFF Pharmaceuticals, Inc. reported fiscal quarter ended March 31, 2024 results: net income Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7.
  - Period: fiscal quarter ended March 31, 2024
  - Net income: Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7
  - Result: reported results
  source text: Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7.1 million for the year ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024042919/0001213900-24-042919-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.